Subscribe or Manage Preferences
Authored Items
Hypermobility Syndrome Underrecognized, Requires Team-Based Management
Wayne Kuznar
VBCR - October 2016, Vol 5, No 5 in Rheumatic Diseases
Neuropathies in Rheumatic Diseases Encompass Wide Spectrum of Diagnoses
Wayne Kuznar
VBCR - October 2016, Vol 5, No 5 in Rheumatic Diseases
Patients with Rheumatoid Arthritis Cite Improvements in Pain, Quality of Life as Treatment Goals
Wayne Kuznar
VBCR - October 2016, Vol 5, No 5 in Rheumatoid Arthritis
Celecoxib Demonstrates Better Results than Acetaminophen in Patients with Low Back Pain
Wayne Kuznar
VBCR - August 2016, Vol 5, No 4 in Back Pain
Entrectinib Shows Strong Activity Against a Range of Rare Solid Tumors with Molecular Abnormalities
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5 in Emerging Therapies
Promising Antitumor Activity of ODM-201 in Metastatic Prostate Cancer
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5 in Emerging Therapies
Updated NCCN Guideline Calls for EGFR Mutations Testing in All Patients with NSCLC
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5 in Lung Cancer
Minor Changes in Systemic Therapy Recommendations in NCCN Breast Cancer Guideline
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5 in Breast Cancer
Nivolumab Monotherapy Prolongs Survival in Patients with Advanced Melanoma
Wayne Kuznar
VBCC - June 2016, Vol 7, No 5 in Melanoma
NCCN Panel Examines Impact of the Presidential Election on Cancer Care
Wayne Kuznar
VBCC - May 2016, Vol 7, No 4 in NCCN Conference Highlights
Vice President Biden Promises to Remove Political Barriers to Research, Calls for Cooperation
Wayne Kuznar
VBCC - May 2016, Vol 7, No 4 in AACR Meeting Highlights
Updated NCCN Multiple Myeloma Guideline Expands Patient Eligibility and Therapeutic Options
Wayne Kuznar
VBCC - May 2016, Vol 7, No 4 in NCCN Conference Highlights
Immunotherapy Takes Center Stage in the Updated NCCN Guideline for Advanced Melanoma
Wayne Kuznar
VBCC - May 2016, Vol 7, No 4 in NCCN Conference Highlights
NCCN Evidence Blocks Help Frame Value-Based Decisions for Systemic Therapies
Wayne Kuznar
VBCC - May 2016, Vol 7, No 4 in NCCN Conference Highlights
Pembrolizumab Elicits High Response in Merkel-Cell Carcinoma
Wayne Kuznar
VBCC - May 2016, Vol 7, No 4 in AACR Meeting Highlights
Medical Costs, Lost Productivity Are Substantial for Chronic Migraine
Wayne Kuznar
VBCN - April 2016 Volume 3, No 1 in Migraine
CSF Biomarkers and Amyloid PET Equally Accurate in Identifying Early-Stage Alzheimer’s Disease
Wayne Kuznar
VBCN - April 2016 Volume 3, No 1 in Alzheimer’s Disease/Dementia
Call to Action: Epilepsy-Related Mortality Should Become a Public Health Priority
Wayne Kuznar
VBCN - April 2016 Volume 3, No 1 in Epilepsy Update
Uncovering Molecular Genetic Basis in Multiplex Families with Epilepsy
Wayne Kuznar
VBCN - April 2016 Volume 3, No 1 in Epilepsy Update
Oncology Medical Home Shows Significant Cost-Savings, Improved Care Delivery
Wayne Kuznar
VBCC - December 2015, Vol 6, No 11 in AVBCC 2015 5th Annual Conference
Urine Biopsies Detect Early Mutations in Patients with Advanced Cancers
Wayne Kuznar
VBCC - December 2015, Vol 6, No 11 in Personalized Medicine
Getting to Value-Based Cancer Care in the ’Omics Era Requires Data Integration
Wayne Kuznar
VBCC - December 2015, Vol 6, No 11 in AVBCC 2015 5th Annual Conference
Nursing Certification Through Portfolio Promotes Professional Development and Performance
Wayne Kuznar
VBCR - December 2015, Volume 4, No 6 in Online First, The Rheumatology Nurse
NCCN Incorporates Affordability Criteria in Its Clinical Guidelines to Assess Value of Cancer Therapies
Wayne Kuznar
VBCC - November 2015, Vol 6, No 10 in NCCN Conference Highlights
Next-Generation Sequencing Propelling Forward Cancer Knowledge, Therapy
Wayne Kuznar
VBCC - November 2015, Vol 6, No 10 in AVBCC 2015 5th Annual Conference
Understanding the Role and Impact of Biosimilars in Rheumatology
Wayne Kuznar
VBCR - October 2015, Volume 4, No 5 in RNS Conference News
FDA Issues Draft Guidance on Naming of Biosimilars
Wayne Kuznar
VBCR - October 2015, Volume 4, No 5 in FDA News & Updates
Pain Management in Pediatric Patients: Focus on Function
Wayne Kuznar
VBCR - October 2015, Volume 4, No 5 in RNS Conference News
Assess Vaccine Status at Initial Patient Visit
Wayne Kuznar
VBCR - October 2015, Volume 4, No 5 in RNS Conference News
An Accountable Payment Model a “Win-Win-Win” Solution to Value-Based Care
Wayne Kuznar
VBCC - October 2015, Vol 6, No 9 in AVBCC 2015 5th Annual Conference
Value Proposition of Oncology Pharmaceuticals: Drug Manufacturers Increasing Focus on Patient Support
Wayne Kuznar
VBCC - October 2015, Vol 6, No 9 in AVBCC 2015 5th Annual Conference Abstracts
Enzalutamide Outperforms Bicalutamide in 2 Trials of Prostate Cancer
Wayne Kuznar
VBCC - September 2015, Vol 6, No 8 in Prostate Cancer
Oncology Pipeline Full, and Not Just with Immunotherapies
Wayne Kuznar
VBCC - September 2015, Vol 6, No 8 in Emerging Therapies
Oncology Specialty Pharmacy Promotes the Coordination of Care
Wayne Kuznar
VBCC - September 2015, Vol 6, No 8 in AVBCC 2015 5th Annual Conference
Oncology Medical Home Accreditation by Community Oncology Alliance Making Progress
Wayne Kuznar
VBCC - September 2015, Vol 6, No 8 in AVBCC 2015 5th Annual Conference
Cancer Drugs Continue to Drive Pharmaceutical Spending Trends
Wayne Kuznar
VBCC - August 2015, Vol 6, No 7 in AVBCC 2015 5th Annual Conference
Care Pathway for NSCLC Cuts Chemotherapy Cost
Wayne Kuznar
VBCC - August 2015, Vol 6, No 7 in Economics of Cancer Care
Cell Surface Amino Acid Potential as Prostate Cancer Biomarker
Wayne Kuznar
VBCC - August 2015, Vol 6, No 7 in Personalized Medicine
High-Value Narrow Networks and Patient Safety Organizations the Future of Cancer Care
Wayne Kuznar
VBCC - August 2015, Vol 6, No 7 in AVBCC 2015 5th Annual Conference
Personalized Medicine Affordability Lies in Enhanced Predictors of Response to Therapy
Wayne Kuznar
VBCC - August 2015, Vol 6, No 7 in AVBCC 2015 5th Annual Conference
The Push Toward Value-Based Payment for Oncology
Wayne Kuznar
VBCC - July 2015, Vol 6, No 6 in Value in Oncology
Lenvatinib Extends Survival in Metastatic Renal-Cell Carcinoma
Wayne Kuznar
VBCC - July 2015, Vol 6, No 6 in ASCO 2015 Highlights
Expert Panel Discusses Quality Measures, Data Collection, and Outcomes in Oncology
Wayne Kuznar
VBCC - June 2015, Vol 6, No 5 in AVBCC 2015 5th Annual Conference
Risk Management a Key Challenge in the New Oncology Payment Models
Wayne Kuznar
VBCC - June 2015, Vol 6, No 5 in AVBCC 2015 5th Annual Conference
Comprehensive Genomic Profiling Enables Efficient “N of 1” Trials
Wayne Kuznar
VBCC - June 2015, Vol 6, No 5 in AVBCC 2015 5th Annual Conference
Pathways Reduce Care Variation and Cost of Care, Improve Overall Outcomes
Wayne Kuznar
VBCC - June 2015, Vol 6, No 5 in AVBCC 2015 5th Annual Conference
“Data in Motion” Will Promote Patient-Centric Care Models
Wayne Kuznar
VBCC - June 2015, Vol 6, No 5 in AVBCC 2015 5th Annual Conference
Immunotherapy Makes Headwinds into Liver Cancer
Wayne Kuznar
VBCC - June 2015, Vol 6, No 5 in ASCO 2015 Highlights
AVBCC 5th Conference: Continuing Challenges for Optimizing Value in Oncology
Wayne Kuznar
VBCC - May 2015, Vol 6, No 4 in AVBCC 2015 5th Annual Conference
Promising Therapies in Multiple Drug Classes Being Explored for B-Cell Lymphomas
Wayne Kuznar
VBCC - May 2015, Vol 6, No 4 in NCCN 2015 Updates
Many Targeted Drugs in Development for Multiple Myeloma: Monoclonal Antibodies Close to Approval
Wayne Kuznar
VBCC - May 2015, Vol 6, No 4 in NCCN 2015 Updates
In CML, Assess Response to First-Line TKI at 3 Months
Wayne Kuznar
VBCC - May 2015, Vol 6, No 4 in NCCN 2015 Updates
Pathways Have the Potential to Deliver Personalized Medicine
Wayne Kuznar
VBCC - May 2015, Vol 6, No 4 in AVBCC 2015 5th Annual Conference
NCCN Panel Addresses Value-Based Care in Oncology
Wayne Kuznar
VBCC - April 2015, Vol 6, No 3 in Economics of Cancer Care
Treatment for CLL Will Incorporate More Targeted Therapies in the Near Future
Wayne Kuznar
VBCC - April 2015, Vol 6, No 3 in NCCN Conference Highlights
NCCN Issues New Smoking-Cessation Guidelines for Patients with Cancer
Wayne Kuznar
VBCC - April 2015, Vol 6, No 3 in NCCN Conference Highlights
Immune Checkpoint Blockade Shows Durable Responses in Lung and Kidney Cancers, Metastatic Melanoma
Wayne Kuznar
VBCC - April 2015, Vol 6, No 3 in NCCN Conference Highlights
Updated NCCN Guideline for Prostate Cancer Allows Early Treatment with Docetaxel
Wayne Kuznar
VBCC - April 2015, Vol 6, No 3 in NCCN Conference Highlights
Value of New Drugs for Hematologic Cancers—Improving Quality, Extending Survival
Wayne Kuznar
VBCC - March 2015, Vol 6, No 2 in Economics of Cancer Care
Blinatumomab Immunotherapy Attacks Minimal Residual Disease in ALL, Leads to High Rates of Complete Response
Wayne Kuznar
VBCC - March 2015, Vol 6, No 2 in Leukemia
Vosaroxin, a Quinolone Derivative, Extends Survival in Older Patients with Acute Myeloid Leukemia
Wayne Kuznar
VBCC - March 2015, Vol 6, No 2 in Leukemia
Monitoring Response to TKI Therapy by PCR Improves Outcomes in Chronic Myeloid Leukemia
Wayne Kuznar
VBCC - March 2015, Vol 6, No 2 in Leukemia
Immunotherapy with PD-1 Inhibitors the Newest Break­­through in Hodgkin Lymphoma
Wayne Kuznar
VBCC - February 2015, ASH 2014 Highlights in Lymphoma
The Hematology Pipeline Is Abundant
Kate Smith, Wayne Kuznar
VBCC - February 2015, ASH 2014 Highlights in Emerging Therapies
Once Off Patent, Imatinib Will Be the Most Cost-Effective Treatment for Newly Diagnosed CML
Wayne Kuznar
VBCC - February 2015, ASH 2014 Highlights in Health Economics
Orphan Drug Expenditures in the United States Expected to Stabilize
Wayne Kuznar
VBCC - February 2015, ASH 2014 Highlights in Health Economics
Pracinostat-Azacitidine Combination Generates Responses in Older Adults with Acute Myeloid Leukemia
Wayne Kuznar
VBCC - February 2015, ASH 2014 Highlights in Leukemia
Sorafenib Prolongs Event- and Relapse-Free Survival in Acute Myeloid Leukemia
Wayne Kuznar
VBCC - February 2015, ASH 2014 Highlights in Leukemia
CAR-T Achieves High Rate of Remission in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia
Wayne Kuznar
VBCC - February 2015, ASH 2014 Highlights in Leukemia
Immunotherapy’s Future May Be in Combinations
Wayne Kuznar
VBCC - February 2015, Vol 6, No 1 in GI Cancers Symposium
More Evidence that Low Vitamin D Levels Reduce Survival in Metastatic Colorectal Cancer
Wayne Kuznar
VBCC - February 2015, Vol 6, No 1 in GI Cancers Symposium
PD-L1 Inhibitor Pembrolizumab Produces Good Responses in Advanced Gastric Cancer
Wayne Kuznar
VBCC - February 2015, Vol 6, No 1 in GI Cancers Symposium
FOLFOXIRI Regimen a New Upfront Option for Some Patients with Metastatic Colorectal Cancer
Wayne Kuznar
VBCC - February 2015, Vol 6, No 1 in GI Cancers Symposium
Use of Advanced Practice Providers May Accrue Cost-Savings in Stem-Cell Transplant
Wayne Kuznar
VBCC - February 2015, Vol 6, No 1 in Economics of Cancer Care
Multiple Myeloma No Longer Considered a Single Disease Entity, as Reflected by New Treatment Regimens
Wayne Kuznar
VBCC - February 2015, Vol 6, No 1 in ASH 2014 Highlights
First-Line Therapy Failure in Patients with MDS Incurs High Financial Burden
Wayne Kuznar
VBCC - February 2015, Vol 6, No 1 in ASH 2014 Highlights
Genomic Landscape of Pancreatic Cancer Being Uncovered, Showing 4 Common Mutations, with KRAS Almost Ubiquitous
Wayne Kuznar
VBCC - February 2015, Vol 6, No 1 in Personalized Medicine
Immunotherapy the Newest Breakthrough in Hodgkin Lymphoma
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10 in ASH 2014 Highlights
Diagnostic Tests Will Face Value-Based Pricing Under Payment Reform
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10 in AVBCC 2014 4th Annual Conference
Providing Financial Incentives for Patients with Cancer to Participate in Their Care Improves Efficiency
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10 in AVBCC 2014 4th Annual Conference
Medical Stop-Loss Insurance About to Get Riskier as Oncology Drug Pipeline Gets Pricier
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10 in AVBCC 2014 4th Annual Conference
Cancer Drug Pricing in the United States: What Is Driving the High Costs?
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10 in ASH 2014 Highlights
Payers Debate the Economics of Personalized Medicine in Oncology
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10 in Economics of Cancer Care
Genetic Profiling Can Identify “Actionable” Mutations in Tumors That Are Missed by Traditional Tests
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10 in Personalized Medicine
New Approaches to Treatment in the Era of Molecular Biomarkers
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10 in Personalized Medicine
New Oncology Models Emerging with Shift from Volume-Based to Value-Based Reimbursement
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10 in AVBCC 2014 4th Annual Conference
Pathways-Based Cancer Care Reduces Hospitalizations, Care Variation, and Costs
Wayne Kuznar
VBCC - December 2014, Vol 5, No 10 in AVBCC 2014 4th Annual Conference
Personalized Medicine in Oncology: NICE Grappling with Assigning Value to New Diagnostics and Medical Technologies
Wayne Kuznar
VBCC - November 2014, Vol 5, No 9 in Personalized Medicine
Individualizing Dosing of 5-FU with Pharmacokinetic Test Is Cost-Effective
Wayne Kuznar
VBCC - November 2014, Vol 5, No 9 in Economics of Cancer Care
Routine Imaging Costly in B-Cell Lymphoma, Rarely Picks Up Relapse After Remission
Wayne Kuznar
VBCC - November 2014, Vol 5, No 9 in Economics of Cancer Care
Adoption of Private Health Exchanges by Employers Expected to Grow Rapidly
Wayne Kuznar
VBCC - November 2014, Vol 5, No 9 in AVBCC 2014 4th Annual Conference
The Changing Healthcare Payment, Regulation, and Delivery Environments
Wayne Kuznar
VBCC - November 2014, Vol 5, No 9 in AVBCC 2014 4th Annual Conference
Cost Levers Increasingly Being Incorporated into Health Benefit Designs
Wayne Kuznar
VBCC - November 2014, Vol 5, No 9 in AVBCC 2014 4th Annual Conference
Employers Are Now Viewing Healthcare as an Investment Rather than an Expense
Wayne Kuznar
VBCC - November 2014, Vol 5, No 9 in AVBCC 2014 4th Annual Conference
Shifts to Value-Based Care and Payment Models Are Improving Quality of Care
Wayne Kuznar
VBCR - October 2014, Volume 3, No 5 in Health Economics
HER2-Derived Vaccine Cuts Recurrences in Patients with High-Risk Breast Cancer
Wayne Kuznar
VBCC - October 2014, Vol 5, No 8 in Breast Cancer
Adding Luteinizing Hormone-Releasing Hormone Agonist to Chemotherapy Preserves Fertility in Women with Breast Cancer
Wayne Kuznar
VBCC - October 2014, Vol 5, No 8 in Breast Cancer
Does Comparative Effectiveness Research Have Value in Oncology?
Wayne Kuznar
VBCC - October 2014, Vol 5, No 8 in AVBCC 2014 4th Annual Conference
Oncology Medical Home Pilot Improves Outcomes
Wayne Kuznar
VBCC - October 2014, Vol 5, No 8 in AVBCC 2014 4th Annual Conference
Managing Cancer at the Workplace Enhances Productivity, Has Value for Employers
Wayne Kuznar
VBCC - October 2014, Vol 5, No 8 in AVBCC 2014 4th Annual Conference
Cancer Support Community: Empowering Patients through Knowledge and Psychosocial Care
Wayne Kuznar
VBCC - October 2014, Vol 5, No 8 in AVBCC 2014 4th Annual Conference
Patient-Centered Oncology Medical Home Improves Health Outcomes at Lower Costs to Patients and Payers
Wayne Kuznar
VBCC - October 2014, Vol 5, No 8 in AVBCC 2014 4th Annual Conference
Maximizing Value and Quality in Gynecologic Cancer Care—Work in Progress
Wayne Kuznar
VBCC - September 2014 Vol 5, No 7 in Value in Oncology
Predictive Testing Holds More Value to Oncology Stakeholders than Prognostic Testing
Wayne Kuznar
VBCC - September 2014 Vol 5, No 7 in AVBCC 2014 4th Annual Conference
Improving the Value Paradigm in Drug Development Will Require More Efficient Clinical Trials, New Biomarkers
Wayne Kuznar
VBCC - September 2014 Vol 5, No 7 in AVBCC 2014 4th Annual Conference
Payer Challenges in Oncology: Establishing Standards and Access to Quality Care
Wayne Kuznar
VBCC - September 2014 Vol 5, No 7 in AVBCC 2014 4th Annual Conference
Comparative Effectiveness Research Helps Define Value in Cancer Care
Wayne Kuznar
VBCC - September 2014 Vol 5, No 7 in AVBCC 2014 4th Annual Conference
Oncologists Can Become Value-Based Providers Using Evidence to Guide Patient Care
Wayne Kuznar
VBCC - September 2014 Vol 5, No 7 in Value in Oncology
Next-Generation Sequencing Provides Value to Multiple Stakeholders
Wayne Kuznar
VBCC - September 2014 Vol 5, No 7 in AVBCC 2014 4th Annual Conference
Should You Consider the Interests of Society at Large When Treating the Individual Patient?
Wayne Kuznar
VBCC - September 2014 Vol 5, No 7 in Value in Oncology
Shifts to Value-Based Care and Payment Models Are Improving Quality of Care
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6 in Reimbursement
Adjuvant Exemestane More Effective than Tamoxifen in Early-Stage Breast Cancer
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6 in Breast Cancer
Upfront Docetaxel Markedly Improves Survival
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6 in Prostate Cancer
Oncology Pipeline Bustling, But Value Concerns Lead to Increased Payer Scrutiny
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6 in AVBCC 2014 4th Annual Conference
Using IBM Watson Electronic System to Guide Patient Management in Oncology
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6 in AVBCC 2014 4th Annual Conference
Big Data and CancerLinQ Can Help to Optimize Patient Outcomes in Oncology
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6 in AVBCC 2014 4th Annual Conference
QOPI Measures Identify Areas for Quality Improvement in Oncology Practice
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6 in AVBCC 2014 4th Annual Conference
Necitumumab Extends Survival of Patients with Squamous Lung Cancer
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6 in Lung Cancer
Patients with Cancer Are Not Asking for Low-Value Tests or Therapies
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6 in Economics of Cancer Care
Most Hospital Readmissions Not Preventable for Patients with Cancer
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6 in Economics of Cancer Care
Even When Adjusting for Improved Survival, Newer Anticancer Drugs Are More Expensive than Older Ones
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6 in Economics of Cancer Care
2014 Oncology Pipeline Looks Impressive
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6 in Emerging Therapies
Patients with Cancer Need Psychosocial Support, Expression of Caring
Wayne Kuznar
VBCC - August 2014 Vol 5, No 6 in AVBCC 2014 4th Annual Conference
Neurologists Must Maintain Patient-Centered Care Even When Facing Economic Pressures
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2 in Health Economics
Fourfold Variability Found in Hospital Charges for Stroke Diagnostic Tests
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2 in Stroke
Earlier Use of Adjunctive Antiepileptic Drugs in Patients with Refractory Disease Could Reduce Costs
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2 in Health Economics
Is No Evidence of Disease Activity an Achievable Goal in Patients with RRMS?
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2 in Multiple Sclerosis
Medical Marijuana Helpful for Some MS Symptoms
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2 in Multiple Sclerosis
Extended Natalizumab Dosing May Reduce PML Risk in Patients with Multiple Sclerosis
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2 in Multiple Sclerosis
Knowledge of Antiepileptic Drug Formulations Key to Accurate Prescribing
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2 in Epilepsy Management
Breakthrough Seizures in Treatment-Adherent Patients Are Costly
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2 in Epilepsy Management
Precision Medicine in the Treatment of Epilepsy
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2 in Personalized Medicine in Neurology
Using Genomics in Clinical Practice in Neurology
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2 in Personalized Medicine in Neurology
Novel Protocol Improves Cognition, Outperforms Community Treatment of Dementia
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2 in Alzheimer’s Disease/Dementia
Two Monoclonal Antibodies Hold Promise of Migraine Prevention
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2 in Migraine
Breath-Powered Intranasal Sumatriptan Has Rapid Absorption, Provides Fast Migraine Relief
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2 in Migraine
Significant Hurdles Must Be Overcome to Actualize the Value of Personalized Medicine
Wayne Kuznar
VBCC - June 2014 Vol 5, No 5 in AVBCC 2014 4th Annual Conference
The Value of Personalized Medicine Lies in Evidence Thresholds, Drug Testing, and Pricing Trends
Wayne Kuznar
VBCC - June 2014 Vol 5, No 5 in AVBCC 2014 4th Annual Conference
Worksite Health Centers Can Help Employees Manage Cancer
Wayne Kuznar
VBCC - June 2014 Vol 5, No 5 in AVBCC 2014 4th Annual Conference
Worksite Pharmacies Can Enhance Overall Drug Management of Patients with Cancer
Wayne Kuznar
VBCC - June 2014 Vol 5, No 5 in AVBCC 2014 4th Annual Conference
Patients with Cancer Want but Are Not Getting Information on the Cost of Their Therapy
Wayne Kuznar
VBCC - June 2014 Vol 5, No 5 in ASCO 2014 Highlights
Delaying ADT for PSA-Only Relapse May Be Viable Option for Men with Prostate Cancer and PSA-Only Relapses
Wayne Kuznar
VBCC - June 2014 Vol 5, No 5 in ASCO 2014 Highlights
AVBCC Expert Panel: Impact of Personalized Medicine on Future and Current Therapies
Wayne Kuznar
VBCC - June 2014 Vol 5, No 5 in AVBCC 2014 4th Annual Conference
Emerging Targeted Therapies for Advanced Pancreatic Cancer Show Promise
Wayne Kuznar
VBCC - May 2014 Vol 5, No 4 in Pancreatic Cancer
Updated NCCN Survivorship Guidelines
Wayne Kuznar
VBCC - May 2014 Vol 5, No 4 in Survivorship
Advances in the Treatment of Patients with Castration-Resistant Prostate Cancer
Wayne Kuznar
VBCC - May 2014 Vol 5, No 4 in Prostate Cancer
Treatment Paradigm for Lung Cancer Shifting Toward Targeted Therapies, Immunotherapy
Wayne Kuznar
VBCC - May 2014 Vol 5, No 4 in Lung Cancer
AVBCC Fourth Conference: Optimizing Value and Stakeholder Integration in Cancer Care
Wayne Kuznar
VBCC - May 2014 Vol 5, No 4 in AVBCC 2014 4th Annual Conference
Payers Facing Multiple Challenges in Ensuring Access to Cancer Care
Wayne Kuznar
VBCC - May 2014 Vol 5, No 4 in AVBCC 2014 4th Annual Conference
Implications of the ACA for Cancer Care
Wayne Kuznar
VBCC - April 2014 Vol 5, No 3 in Economics of Cancer Care
Ramucirumab Improves Survival as Second-Line Therapy in Patients with Advanced Gastric Cancer
Wayne Kuznar
VBCC - April 2014 Vol 5, No 3 in Gastric Cancer
New Molecular Test to Monitor Breast Cancer Recurrence by Sequencing Circulating Tumor Cells
Wayne Kuznar
VBCC - April 2014 Vol 5, No 3 in Personalized Medicine
Personalized Cancer Care: Combination Therapies May Be Key to Hitting Tumor Heterogeneity
Wayne Kuznar
VBCC - April 2014 Vol 5, No 3 in Personalized Medicine
In the Real World, Bevacizumab Improves Survival in Patients with Metastatic Colorectal Cancer
Wayne Kuznar
VBCC - April 2014 Vol 5, No 3 in Colorectal Cancer
Updated NCCN Guidelines for Non-Hodgkin Lymphoma Note Controversy Related to B-Cell Disease Management
Wayne Kuznar
VBCC - April 2014 Vol 5, No 3 in NCCN 2014 Conference
Updated NCCN Melanoma Guideline Adds BRAF Inhibitor and MEK Inhibitor to First-Line Targeted Therapeutic Options
Wayne Kuznar
VBCC - April 2014 Vol 5, No 3 in NCCN 2014 Conference
New Pathways, Targeted Therapies Being Explored in Hepatocellular Carcinoma
Wayne Kuznar
VBCC - March 2014, Volume 5, No 2 in Pathways
Switching from Intravenous to Subcutaneous Rituximab Saves Staff Time and Money
Wayne Kuznar
VBCC - March 2014, Volume 5, No 2 in Economics of Cancer Care
Understanding Molecular Subtypes Is Basis for Genomic Medicine in Prostate Cancer
Wayne Kuznar
VBCC - March 2014, Volume 5, No 2 in Personalized Medicine
Biomarker Development and Validation Crucial to Appropriate Use of Emerging Treatments in Oncology
Wayne Kuznar
VBCC - March 2014, Volume 5, No 2 in Personalized Medicine
Immunotherapy Holds Promise to Extend Survival in GI Cancers
Wayne Kuznar
VBCC - March 2014, Volume 5, No 2 in Immunotherapy
Hematologic Drug Pipeline Boasts Novel Approaches
Wayne Kuznar
VBCC - February 2014, Volume 5, No 1 in Emerging Therapies
Decitabine More Cost-Effective than Conventional Induction in Older Patients with AML
Wayne Kuznar
VBCC - February 2014, Volume 5, No 1 in Economics of Cancer Care
Physicians Must Consider the Financial Burden Associated with Allogeneic Transplants
Wayne Kuznar
VBCC - February 2014, Volume 5, No 1 in Economics of Cancer Care
Rituximab Infusions Costlier When Given in the Hospital than in the Office Setting
Wayne Kuznar
VBCC - February 2014, Volume 5, No 1 in Economics of Cancer Care
Significant Hospital Costs Tied to 30-Day Readmissions for Allogeneic Transplants
Wayne Kuznar
VBCC - February 2014, Volume 5, No 1 in Economics of Cancer Care
Peripheral T-Cell Lymphoma Associated with High Clinical Burden, Resource Utilization, and Costs
Wayne Kuznar
VBCC - February 2014, Volume 5, No 1 in Economics of Cancer Care
Genetics Providing New Insights into Signaling Pathways and Treatment Targets in ALL
Wayne Kuznar
VBCC - February 2014, Volume 5, No 1 in Personalized Medicine
Adjuvant Chemotherapy Benefit in Stage II Colon Cancers Is Small, May Even Cause Harm, Depending on Prognostic Markers
Wayne Kuznar
VBCC - February 2014, Volume 5, No 1 in GI Cancers Symposium
Rheumatology Nursing Is Evolving Rapidly, Prominent Role Already Assumed
Wayne Kuznar
VBCR - February 2014, Volume 3, No 1 in The Rheumatology Nurse
Investigational Anti–IL-6 Monoclonal Antibody Shows Promising Response Rates in RA
Wayne Kuznar
VBCR - February 2014, Volume 3, No 1 in Rheumatoid Arthritis
Biologics May Not Be the Cost Savers They Are Assumed to Be in RA
Wayne Kuznar
VBCR - February 2014, Volume 3, No 1 in Health Economics
Step-Therapy Drug Policies Rarely Limit Utilization of High-Cost Specialty Pharmaceuticals
Wayne Kuznar
VBCR - February 2014, Volume 3, No 1 in Health Economics
JAK Inhibitors and Other Biologics Are the Future of RA Treatment
Wayne Kuznar
VBCR - February 2014, Volume 3, No 1 in Rheumatoid Arthritis
Investigational IL-17 Inhibitor Induces Clinical Response in Patients with Psoriatic Arthritis
Wayne Kuznar
VBCR - February 2014, Volume 3, No 1 in Psoriatic Arthritis
National Survey Results: Rheumatologists Not Treating Patients with Gout Aggressively Enough
Wayne Kuznar
VBCR - February 2014, Volume 3, No 1 in Gout
In Systemic Lupus Erythematosus, Glucocorticoid Dose Linked to Adverse Events and Overall Costs
Wayne Kuznar
VBCR - February 2014, Volume 3, No 1 in Lupus
Consideration of Pathogenesis Leads to Appropriate Therapy in Patients with Severe Thrombocytopenia and Lupus
Wayne Kuznar
VBCR - February 2014, Volume 3, No 1 in Lupus
The Top 5 Things You May Have Missed at SABCS
Wayne Kuznar
VBCC - Meeting Highlights in SABCS 2013
Triple-Negative Breast Cancer Continues to Confound, New Approaches Being Explored
Wayne Kuznar
VBCC - Meeting Highlights in SABCS 2013
Effective End-of-Life Care Means Symptom Management, Preserving Quality of Life
Wayne Kuznar
VBCC - Meeting Highlights in SABCS 2013
Reexamination of Evidence Supports Routine Mammography to Prevent Breast Cancer Death
Wayne Kuznar
VBCC - Meeting Highlights in SABCS 2013
Practical Problems Must Be Overcome to Move Personalized Medicine Forward in Oncology
Wayne Kuznar
VBCC - November 2013, Volume 4, No 9 in Personalized Medicine
Next-Generation Sequencing Identifies “Actionable” Genomic Alterations in Solid Tumors
Wayne Kuznar
VBCC - November 2013, Volume 4, No 9 in Personalized Medicine
Bronchial/Nasal Gene-Expression Tests for Early Detection of Lung Cancer
Wayne Kuznar
VBCC - November 2013, Volume 4, No 9 in Personalized Medicine
Redesigning Clinical Trials Necessary to Enhance Discovery of Effective Targeted Drugs in the Genomic Era
Wayne Kuznar
VBCC - October 2013, Volume 4, No 8 in Personalized Medicine
Emerging Therapies and New Approaches in the “Double-Refractory” Setting in Myeloma
Wayne Kuznar
VBCC - September 2013, Volume 4, No 7 in Drug Update
New Technologies Bring No Upward Shift in Treatment of Local Prostate Cancer
Wayne Kuznar
VBCC - September 2013, Volume 4, No 7 in Prostate Cancer
Chemotherapy-Induced Neuropathy Can Persist a Decade after Stopping Treatment for Colorectal Cancer
Wayne Kuznar
VBCC - September 2013, Volume 4, No 7 in Drug Update
Mammography Screening Rates Enhanced by Copay Elimination
Wayne Kuznar
VBCC - September 2013, Volume 4, No 7 in Economics of Cancer Care
Poor Adherence to Oral Cancer Drugs a Growing Concern
Wayne Kuznar
VBCC - September 2013, Volume 4, No 7 in Economics of Cancer Care
Causes for Hospital Readmissions of Patients with Cancer
Wayne Kuznar
VBCC - September 2013, Volume 4, No 7 in Economics of Cancer Care
ASCO President Highlights Bridges to Conquer Cancer
Wayne Kuznar
VBCC - July 2013, Volume 4, No 6 in Economics of Cancer Care
Variations in Cancer Treatment Raise Average Cost of Care by $25,000 per Patient
Wayne Kuznar
VBCC - June 2013, Volume 4, No 5 in ASCO Annual Meeting
Bevacizumab an Effective New Treatment Option for Relapsed Cervical Cancer
Wayne Kuznar
VBCC - June 2013, Volume 4, No 5 in ASCO Annual Meeting
Use of High-Cost Tests for Lung Cancer Surveillance Rising
Wayne Kuznar
VBCC - June 2013, Volume 4, No 5 in Economics of Cancer Care
Update on Initial Therapy of Multiple Myeloma and Emerging Agents for the Refractory Setting
Wayne Kuznar
VBCM - Meeting Highlights in ASCO 2013
Variations in Cancer Treatment Raise Average Cost of Care by $25,000 Per Patient
Wayne Kuznar
VBCC - News
Bevacizumab an Effective New Treatment Option for Relapsed Cervical Cancer
Wayne Kuznar
VBCC - News
Personalized Immunotherapy plus Sunitinib Doubles Survival in Advanced Kidney Cancer
Wayne Kuznar
VBCC - March 2013, Volume 4, No 3 in Personalized Medicine
Ruxolitinib Treatment Reduces Myelofibrosis Symptoms, Spleen Size
Wayne Kuznar
VBCC - February 2013, Volume 4, No 2 in ASH Annual Meeting
Ponatinib Produces High Response Rates in Hard-to-Treat Leukemia
Wayne Kuznar
VBCC - January 2013, Volume 4, No 1 in ASH Annual Meeting
Unforeseen Hospital Admissions Are Frequent for Patients Receiving Radiotherapy
Wayne Kuznar
VBCC - July 2012, Volume 3, No 5 in ASCO Annual Meeting
Cancer Screening Saves Lives, Is Cost-Effective
Wayne Kuznar
VBCC - July 2012, Volume 3, No 5 in ASCO Annual Meeting
Tivozanib Outperforms Sorafenib as First-Line Treatment in Advanced Renal-Cell Carcinoma
Wayne Kuznar
VBCC - July 2012, Volume 3, No 5 in ASCO Annual Meeting
Quality of Life Drives Patient Preference for Metastatic Renal-Cell Carcinoma Drug
Wayne Kuznar
VBCC - July 2012, Volume 3, No 5 in ASCO Annual Meeting
In Head-to-Head Comparison, Continuous Beats Intermittent Hormonal Therapy for Metastatic Prostate Cancer
Wayne Kuznar
VBCC - June 2012, Volume 3, No 4 in ASCO Annual Meeting
Personalized Vaccine Promising When Added to Sunitinib in Patients with Metastatic Renal-Cell Carcinoma
Wayne Kuznar
VBCC - March 2012, Volume 3, No 2 in Genitourinary Cancers Symposium
Dose Escalation of Axitinib as Second-Line Treatment of mRCC May Be Needed to Optimize Outcome
Wayne Kuznar
VBCC - March 2012, Volume 3, No 2 in Genitourinary Cancers Symposium
Many Patients with mRCC Ineligible for Clinical Trials
Wayne Kuznar
VBCC - March 2012, Volume 3, No 2 in Genitourinary Cancers Symposium
External Beam Radiation More Toxic, Costlier than Brachytherapy or Prostatectomy
Wayne Kuznar
VBCC - March 2012, Volume 3, No 2 in Genitourinary Cancers Symposium
Understanding the 340B Drug Pricing Program Requirements
Wayne Kuznar
VBCC - Other
Comparative Effectiveness Analysis of 3 Radiation Therapies for Prostate Cancer
Wayne Kuznar
VBCC - February 2012, Volume 3, No 1 in Genitourinary Cancers Symposium
High Out-of-Pocket Costs Degrade Quality of Cancer Care
Wayne Kuznar
VBCC - News
Value-Based Insurance Design in Oncology
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4 in Value in Oncology
Payer Trends in Oncology: Challenges and Solutions
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4 in AVBCC Annual Conference
The Role of Molecular Diagnostics in Cancer Treatment
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4 in Cancer Care
Benefit Design Trends in Oncology Management
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4 in Oncology Benefit Edition
NCCN Guidelines Inform Decisions Across the Continuum of Cancer Care
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4 in NCCN Guidelines
The Age of Personalized Oncology Therapies
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4 in Personalized Medicine
A New Option for Metastatic Breast Cancer
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4 in Breast Cancer
Community Oncology Clinics under Increasing Financial Pressure
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4 in Community Oncology
Oncologists Face Economic Challenges while Improving Patient Care
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4 in Practice Management
Patient Navigation and Patient Assistance Programs in Oncology
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4 in Patient Navigation
Oncology Drug Reimbursement and Administration Benchmarks
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4 in Reimbursement
Oncology Pharmacy as a Specialty
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4 in Oncology
Medical and Pharmacy Directors’ Strategies to Improve Cancer Care Management
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4 in Cancer Care
The Impact of Therapy Type on Clinical Fragmentation in Oncology Care
Wayne Kuznar
VBCC - July 2011, Volume 2, No 4 in Oncology
Hospital Implements New Oral Chemotherapy Handling Process in Effort to Increase Safety
Wayne Kuznar
VBCC - February 2011, Volume 2, No 1 in Meeting Highlights
For Overweight Patients, Dosing Chemotherapy Based on Total Body Weight Does Not Lead to More Toxicities
Wayne Kuznar
VBCC - February 2011, Volume 2, No 1 in Meeting Highlights
Cost-Effectiveness Comparison: FOLFIRI versus FOLFOX
Wayne Kuznar
VBCC - February 2011, Volume 2, No 1 in Meeting Highlights
Preventing Emesis Can Save Money
Wayne Kuznar
VBCC - February 2011, Volume 2, No 1 in Meeting Highlights
Economic Analysis of Chemo-Induced Nausea and Vomiting
Wayne Kuznar
VBCC - February 2011, Volume 2, No 1 in Meeting Highlights
Last modified: March 29, 2012
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology